Skip to main content
Heliyon logoLink to Heliyon
. 2023 Jan 14;9(1):e12948. doi: 10.1016/j.heliyon.2023.e12948

Novel N-benzyl-2-oxo-1,2-dihydrofuro [3,4-d]pyrimidine-3(4H)-carboxamide as anticancer agent: Synthesis, drug-likeness, ADMET profile, DFT and molecular modelling against EGFR target

Ayşen Şuekinci Yılmaz 1,, Gühergül Uluçam 1
PMCID: PMC9876965  PMID: 36711281

Abstract

A novel compound N-benzyl-2-oxo-1,2-dihydrofuro [3,4-d]pyrimidine-3(4H)-carboxamide (DHFP) was synthesized by addition, rearrangement, and intramolecular cyclization reactions. The three-dimensional geometry of DHFP has been determined by density functional theory calculations in the gas phase. Thus, the geometrical properties of DHFP such as the bond lengths, bond angles, and dihedral bond angles have been determined in the optimized molecular configuration. Also, the HOMO-LUMO energies were calculated. The charge distribution of the DHFP has been calculated by Natural Population Analysis (NPA) approach. NMR and FTIR spectra were calculated and compared with their experimental corresponding to confirm the synthesis of the DHFP. The anticancer activities of the DHFP were also determined on human colon cancer (HT29) and prostate cancer (DU145) cell lines. Molecular docking studies of the DHFP with EGFR tyrosine kinase, which is responsible for cancer cell proliferation and growth, were performed and it was observed that docking interaction took place. The DHFP has the potential to be a drug, as it is determined that DHFP obeys Lipinski's five rules, can cross the blood-brain barrier, and can be rapidly absorbed from the gastrointestinal wall.

Keywords: Curtius rearrangement, DU145, HT29, HOMO-LUMO, B3LYP

1. Introduction

Pyrimidine, an important nitrogen-containing aromatic heterocyclic compound, is found in the structure of DNA and RNA, which carry the necessary information for life. Many different pyrimidine compounds have been first designed, and then synthesized, and it has been seen that they have quite a lot of biological effects such as anti-proliferative [1], antiviral [2], antitumor [3], anti-inflammatory [4], antibacterial [5], antifungal [6], anti-β-glucuronidase [7]. Also, its anti-Alzheimer [8] and anti-tuberculosis [9] effects have been identified. In addition, the main component of commercial cancer drugs such as cytarabine [10], gemcitabine [11], xeloda [12], and 5-fluorouracil [13] are pyrimidine compounds.

Furopyrimidines are fused ring-containing compounds synthesized by forming a pyrimidine ring on the furan ring by various reactions. In addition, these compounds have many biological properties similar to pyrimidines and have; therefore, been the subject of much research in recent years [[14], [15], [16]]. However, the concerning literature has just a few articles targeting quantum chemical calculations and molecular docking studies on furopyrimidines.

Hossam et al. have published that the anilino-furo [2,3-d]pyrimidine derivatives they synthesized have EGFR tyrosine kinase inhibitory and anti-cancer effects [17]. Han et al. stated that the chiral 6-aryl-furo [2,3-d]pyrimidine-4-amines they synthesized are equipotent to Erlonitib, which is an EGFR tyrosine kinase inhibitor and is used as an anticancer drug [18]. The other study group has shown that polysubstituted thieno [2,3-d]pyrimidine derivatives have EGFR tyrosine kinase inhibitory effect with an IC50 value similar to that of the commercial drug Olmitinib [19]. All these studies are for the furo [2,3-d]pyrimidine skeleton, and we could not find any studies for the furo [3,4-d]pyrimidine skeleton. In this context, we synthesized the new N-benzyl-2-oxo-1,2-dihydrofuro [3,4-d]pyrimidine-3(4H)-carboxamide (DHFP) compound and investigated its EGFR kinase inhibitory and anticancer effect.

Herein, the DHFP geometry has been optimized using density functional theory (DFT) in this study. Vibrational frequencies and structural parameters.of DHFP have been obtained with the Gaussian G09w program [20]. FTIR and NMR have been calculated and compared with the experimental value. The anticancer activities have been investigated in two cell lines (prostate and colon), respectively. Molecular docking studies of compound DHFP with EGFR tyrosine kinase have been performed to evaluate its potential as an anticancer agent. Finally, data on the pharmacokinetic and drug-likeness of DHFP have been obtained using the Swiss ADME [21], and ADMET-SAR programs [22].

2. Materials and methods

2.1. Instruments and reagents

NMR spectra were recorded on Varian Mercury Plus 400 MHz spectrometer at 400 MHz for 1H NMR and 100 MHz for 13C NMR. 13C and 1H NMR spectra were taken using acetone-d6 (for 4-((3-benzylureido)methyl)furan-3-carbonyl azide) (3) and DMSO-d6 (for DHFP) as a solvent. Infrared spectra were recorded on Perkin Elmer FTIR/FIR Spectrophotometer Frontier. All high-resolution mass spectra (HRMS) were measured on UPLC-UHR-Q/TOFABSCIEX Triple TOF 4600. Uncorrected melting points were determined on the Electrothermal melting point analyzer.

4-(isocyanatomethyl)furan-3-carbonyl azide was used as starting material and was synthesized according to the Yılmaz et al. procedure [23]. The chemicals used in the experiments were obtained from commercial sources. All reactions were monitored by TLC (Thin Layer Chromatography) with Merck 0.2 mm silica gel 60 F254 aluminum plates, and silica gel (Merck 70-230 mesh) was used in column chromatography.

2.2. Theoretical method

Molecular configuration and geometrical calculations of DHFP were performed in the Gaussian G09w package program with the basis set of 6-311++G (2d, p) by using the B3LYP theory, which consists of Becke's three-parameter hybrid variable function and Lee-Yang-Parr's correlation function [[24], [25], [26], [27], [28]]. Frontier molecular orbitals and molecular electrostatic potential maps were calculated by the density functional theory B3LYP/6-311++G (2d, p) method. Gauge invariant atomic orbitals (GIAO) method was used for 1H and 13C NMR chemical shifts relative to reference tetramethyl silane (TMS) [29]. Since the experimental data were obtained in dimethyl sulfoxide (DMSO), theoretical calculations were made in DMSO for comparison. To reduce the theoretical errors in the spectrum, the FTIR parameters were multiplied by 0.9613 and a detailed potential energy distribution (PED) analysis was performed using the VEDA program [30]. Visualization of all data was performed in Gauss View 5.0 [20,[31], [32], [33]].

2.3. Anticancer activity

Anticancer activity studies of DHFP were performed on HT29 and DU145 cell lines according to our previous study [34] using the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) method [35] at the Trakya University Technology Research Development Application and Research Center (TUTAGEM).

Cell viability and cell death were calculated as follows:

CellViabilty%=sampleabsorbancecontrolabsorbancex100
CellDeath%=100CellViability%

2.4. Molecular docking

Since many in vivo and in vitro experiments are required, it is very difficult to determine whether the synthesized compounds have biological effects. Molecular docking calculation of ligand-receptor interactions provides us with easier information about the bioactivity of the compound [[36], [37], [38], [39], [40]]. By choosing the lowest energy interaction among the molecular docking results, the best ligand-receptor interaction can be examined. Molecular docking studies were performed with Auto Dock Tools 1. 5. 6 [41,42]. Molecular docking of DHFP with EGFR tyrosine kinase was studied. The 3D crystal structure of EGFR tyrosine kinase was taken from Protein Data Bank (PDB ID:1M17) [43,44]. Water molecules were removed, and polar hydrogens and Kollman United charges were added as the biomolecule was prepared for docking. The DHFP was made ready for use for docking by minimizing its energy at the Gaussian 09w program. Partial charges of DHFP were calculated by Geistenger Method. In grid preparation, the grid box was set as 126 × 126 × 126 Å for x,y and z, respectively with a grid spacing of 0.375 Å and the grid center was set to 23.55, 9.53, 58.35 for x, y and z, respectively. Autodock docking studies were examined by using the Lamarckian Genetic Algorithm (LGA). As a result of the calculations, the lowest energy interaction was selected and the results were interpreted. All of the ligand-protein interactions were illustrated using Pymol [45,46] and Chimera software [47]. PLIP (Protein-Ligand Interaction Profiler) web tool was used to show the H bonds in detail [48].

2.5. Determinations of the data of ADME and ADMET SAR

Evaluation of the bioavailability of compounds using computer-based programs is important in the discovery and development of new drugs. The Lipinski rule assists in categorizing compounds as drug-like and non-drug like by evaluating various parameters (Hydrogen Bond Acceptor, Hydrogen Bond Donor, molecular weight, lipophilicity (log P)) [49]. Physicochemical and pharmacokinetic properties of DHFP obtained by utilizing Swiss ADME http://www.swissadme.ch/index.php free website (Swiss Institute of Bioinformatics, Switzerland) [21]. ADMET (absorption, distribution, metabolism, elimination, toxicity) is an essential part of drug discovery and gives information about the drug's behavior in metabolism. ADMET features of DHFP were obtained using the online database ADMETSAR, http://lmmd.ecust.edu.cn/admetsar2 [50].

3. Result and discussion

3.1. Synthesis of DHFP

Synthesis of N-benzyl-2-oxo-1,2-dihydrofuro [3,4-d]pyrimidine-3(4H)-carboxamide (DHFP) consists of three steps as shown in Fig. 1: The first step is the addition of benzylamine (2) to the isocyanate on 4-(isocyanatomethyl)furan-3-carbonyl azide (1). The second step involves the conversion of the azide group on 4-((3-benzylureido)methyl)furan-3-carbonyl azide (3) to isocyanate (intermediate state) by the Curtius rearrangement reaction. The reaction continued without isolating the intermediate product (4) in the second step. The third step is the synthesis of DHFP by the intramolecular cyclization reaction of 1-benzyl-3-((4-isocyanatofuran-3-yl)methyl)urea (4).

Fig. 1.

Fig. 1

Synthesis of DHFP.

3.1.1. Synthesis of 4-((3-benzylureido)methyl)furan-3-carbonyl azide (3)

0.22 g (1.15 mmol) of 4-(methylisocyanate)furan-3-carbonyl azide (1) was dissolved in 10 mL of dry benzene, 0.14 mL (0.14 g, 1.27 mmol) of benzylamine (2) was added and then stirred at room temperature under nitrogen atmosphere. According to the TLC result, the reaction was finished after 5 min. The precipitate was filtered, and the crude product was purified by column chromatography in a 1:1 ethylacetate: hexane solvent system. 0.43 g 4-((3-benzylureido)methyl)furan-3-carbonyl azide (6) (94%) was obtained as white crystals. Mp: 95.3–97.1 °C, 1H NMR (400 MHz, acetone-d6) δ (ppm): 8.23 (s, 1H, =CH), 7.58 (s, 1H, =CH), 7.2–7.3 (m, 5H, =CH), 6.08 (br. s, 1H, NH), 5.91 (br. s, 1H, NH), 4.39 (d, 2H, CH2), 4.32 (d, 2H, CH2), 13C NMR (100 MHz, acetone-d6) δ (ppm): 172.9 (CON3), 157.7 (NCON), 150.6 (=CH), 143.0 (=CH),128.1 (=CH), 127.1 (2C, =CH), 126.5 (2C, =CH), 124.2 (=C), 119.4 (=CH),119.0 (=C), 43.4 (CH2), 33.7 (CH2), FAR FTIR (cm-1): 3316 (broad, –NH), 2153 (-N3) 1687 (NCON), 1662 (CON3), LC-Q/TOF (exp.) (C14H13O3N5 (+Na)): 322.0937, LC-Q/TOF (theo.) (C14H13O3N5 (+Na)): 322.0916.

3.1.2. Synthesis of N-benzyl-2-oxo-1,2-dihydrofuro [3,4-d]pyrimidine-3(4H)-carboxamide (DHFP)

0.19 g (0.64 mmol) of 4-((3-benzylureido)methyl)furan-3-carbonyl azide (3) was refluxed in 15 mL of dry THF under nitrogen atmosphere for 16 h. The solvent was evaporated, and the crude product was purified by column chromatography of the 2:3 Ethyl acetate/Hexane solvent system. 0.124 g (73.3%) of N-benzyl-2-oxo-1,2-dihydrofuro [3,4-d]pyrimidine-3(4H)-carboxamide (DHFP) was obtained as a white shiny solid. Mp: 218.6–220.1 °C,1H NMR (400 MHz, DMSO-d6) δ (ppm): 9.93 (s, 1H, NH), 9.49 (s, 1H, NH), 7.45 (s, 1H, =CH), 7.31 (s, 1H, =CH), 7.24–7.33 (m, 5H, =CH), 4.77 (s, 2H, CH2), 4.77 (d, 2H, CH2),13C NMR (100 MHz, DMSO-d6) δ (ppm): 155.2 (C]O), 153.4 (C]O), 139.5 (=CH), 137.0 (=C), 128.8 (=C), 127.6 (=C), 127.3 (2C,=CH), 125.3 (2C,=CH), 124.0(=CH), 109.5 (=C), 43.9 (CH2), 39.3 (CH2),LC-Q/TOF (exp.) (C14H14O3N3(+H)): 272.1035, LC-Q/TOF (theo.) (C14H14O3N3(+H)): 272.1035.

Experimental 1H and 13C NMR, FTIR and Q-TOF spectrum data of 3 and DHFP was also given as supplementary data.

3.2. Molecular geometry

DFT/B3LYP/6-311++G (2d, p) method is employed to obtain the geometry of the DHFP by calculating its minimized energy. The molecular geometry of the DHFP is shown in Fig. 2. The parameters for structural analysis such as selected bond lengths, bond angles, and dihedral bond angles are given in Table 1.

Fig. 2.

Fig. 2

Molecular configuration of DHFP.

Table 1.

Theoretical bond lengths (Å), bond angles (◦), and dihedral bond angles (◦) of DHFP in the gas phase. Labels refer to Fig. 2.

Selected Bond Lengths (Å) Selected Bond Angles (°) Selected Dihedral Bond Angles (°)
C1–C2 1.355 C1–O5–C4 107.503 C1–O5–C4–H22 179.236
C1–O5 1.361 C1–C2–C3 105.871 C1–O5–C4–C3 0.521
C2–C3 1.420 C3–C4–H22 134.650 O5–C4–C3–C2 −0.213
C1–H21 1.076 C3–N9–H25 120.953 C1–C2–C3–N9 178.854
C2–C6 1.488 C3–N9–C8 122.632 C2–C3–N9–C8 −20.053
C6–N7 1.489 N9–C8–N7 116.753 C3–N9–C8–O10 −163.966
N7–C8 1.392 N9–C8–O10 118.727 N9–C8–N7–C11 −175.940
C8–N9 1.382 C8–N7–C6 122.352 O10–C8–N7–C11 3.858
C8–O10 1.227 N7–C11–N13 117.046 C8–N7–C11–O12 −178.800
C3–N9 1.390 N7–C11–O12 118.482 C8–N7–C11–N3 1.251
C6–H28 1.096 C11–N13–H26 117.088 O12–C11–N13–H26 179.726
N9–H25 1.009 C11–N13–C14 121.582 O12–C11–N13–C14 −1.631
C11–N7 1.442 H27–C14–H28 107.980 N13–C14–C15–C16 74.990
C11–O12 1.222 C14–C15–C16 120.433 C14–C15–C16–C17 −179.394
C11–N13 1.345 C15–C16–C17 120.484 C15–C16–C17–C18 −0.178
N13–H26 1.015 H29–C16–C17 120.226 H29–C16–C17–H30 0.176
C14–N13 1.460
C14–H27 1.090
C14–C15 1.516
C15–C16 1.398
C16–C17 1.390
C17–C18 1.393
C16–H29 1.084
C17–H30 1.084

The calculated NMR and FTIR spectra are compared with those of experimental spectra to be able to confirm the theoretically obtained geometry of the DHFP for its minimized energy.

The charge distribution in the atoms in the molecule is important for determining the electrostatic interaction and molecular force fields [51,52]. The atomic charge distribution of the DHFP is obtained by Natural Population Analysis (NPA) method within the framework of Gaussian 09 and listed in Table 2. The atomic charge distribution shows that the negative charges localize on the electronegative oxygen and nitrogen atoms, while the positive charges are on the hydrogen atoms in the molecule. Carbon atoms can have negative or positive charges with respect to the electronegative atoms around them. The highest negative charges were found as −0.33848 and −0.33840 on O10 and O12 atoms, respectively. As expected, the highest positive charges were found as 0.42333 and 0.42106 on C8 and C11 atoms, respectively. Since there are three electronegative atoms, two nitrogen, and one oxygen, to which each is bonded, the carbon atoms in question become electron-depleted and positively charged.

Table 2.

Natural Charges of DHFP. Atomic labels refer to Fig. 2.

Atoms NPA Atoms NPA
C1 0.07788 N7 −0.27129
C2 −0.07397 N9 −0.30476
C3 0.03910 N13 −0.32219
C4 0.03988 H21 0.09986
C6 −0.08963 H22 0.09985
C8 0.42333 H23 0.10259
C11 0.42106 H24 0.12582
C14 −0.09479 H25 0.20563
C15 −0.02409 H26 0.21789
C16 −0.09702 H27 0.11421
C17 −0.09703 H28 0.09860
C18 −0.10163 H29 0.10934
C19 −0.09876 H30 0.10143
C20 −0.09957 H31 0.10148
O5 −0.22750 H32 0.10138
O10 −0.33848 H33 0.09980
O12 −0.33840

Atomic charge distribution calculations were also performed using the MPA method. However, the results found with NPA were more consistent than those found with MPA. For example, in the distribution obtained with MPA, the highest positive charges were not found on C8 and C11.

3.3. Experimental and theoretical 13C NMR and 1H NMR chemical shift values

Experimental and theoretical 1H NMR and 13C NMR chemical shift values of DHFP as converted from Hertz units to ppm are listed in Table 3 referencing TMS. The experimental NMR values were taken in DMSO-d6 solvent while theoretical NMR data were calculated in the gas phase and again in DMSO solvent. Eleven hydrogen atoms in the DHFP structure give seven proton NMR signals and can be classified as two hydrogens attached to aliphatic carbons, three hydrogens attached to aromatic carbons, and two hydrogens attached to amines. As expected, 13C NMR shows twelve different carbons in aliphatic, aromatic, and carbonyl structures.

Table 3.

The experimental and theoretical 1H NMR and 13C NMR chemical shift values of DHFP according to TMS δ/ppm (s: singlet, br.: broad, m: multiplet, Assign.: assignments). The hydrogen and carbon labels can be followed from Fig. 2.

1H NMR
Experimental Theoretical
Assign. δ (ppm) Assign. Gas phase DMSO
CH2 4.38 (d) H28 3.58 3.82
H27 5.39 5.27
CH2 4.77 (s) H23 4.17 4.32
H24 5.98 5.90
CH (arom., 5H) 7.24–7.33(m) H33
H31
H32
H30
H29
7.35
7.40
7.47
7.51
8.03
7.58
7.58
7.64
7.64
7.98
CH (arom.) 7.31 (s) H22 6.99 7.18
CH (arom.) 7.45 (s) H21 7.21 7.35
NH 9.49 (br. s) H25 5.54 6.03
NH
9.93 (br.s)
H26
9.49
9.59
13C NMR
Experimental
Theoretical
Assign. δ (ppm) Assign. Gas phase DMSO
CH2 39.31 C6 40.93 41.30
CH2 43.99 C14 46.76 46.35
C (arom.) 109.51 C2 116.22 116.06
CH (arom.) 124.02 C18 131.18 131.51
CH (arom.) 125.35 C16
C20
134.54
132.06
133.96
132.88
CH (arom.) 127.32 C17
C19
133.03
132.01
132.06
132.71
C (arom.) 127.64 C3 132.45 132.19
C (arom.) 128.81 C15 147.91 148.39
CH (arom.) 137.04 C1 141.28 141.85
CH (arom.) 139.55 C4 125.80 127.33
C=O 153.41 C8 158.60 159.73
C=O 155.22 C11 158.95 160.06

The two identical benzylic protons (CH2) give a doublet peak because of the spin-spin interaction of protons in H2C–NH. Experimentally, these protons were observed as a doublet at 4.39 ppm, while theoretically they (H28 and H27) were seen as two separate peaks at 3.82 and 5.27 ppm. The aliphatic identical protons in the CH2 of the pyrimidine ring have a single peak because there is no H on its neighboring atoms. Their experimental corresponding was at 4.77 ppm as a singlet, while the theoretical values of H23 and H24 were at 4.32 and 5.90 ppm, respectively.

Two different aromatic protons of the furan ring give a singlet for each because of the absence of H in their neighboring atoms. The experimental values of furan ring protons, namely H22 and H21 were at 7.31 and 7.45 ppm, whereas their theoretical values were at 7.18 and 7.35 ppm, respectively. The five protons on the ortho (H33, H29), meta (H32, H30), and para (H31) positions of the benzene ring give three different peaks. The signals were split due to the neighboring hydrogen atoms in carbons. While the experimental values of these protons were observed as multiplet in the range of 7.24–7.33 ppm, the theoretical values were 7.58 ppm for H33 and H31, 7.64 ppm for H32 and H30, and 7.98 ppm for H29.

The amine protons must appear as a broad singlet. Indeed, the experimental values of protons of two amines were at 9.49 and 9.93 ppm as a broad singlet, their (H25 and H26) theoretical values were at 6.03 and 9.59 ppm, respectively.

Considering the 13C NMR spectra of the DHFP, the experimental values of the aliphatic carbon on the pyrimidine ring (CH2) and benzylic carbon peak (CH2) were at 39.31 and 43.98 ppm, while the theoretical values of C6 and C14 were at 41.30 and 46.35 ppm, respectively. The eight aromatic carbon peaks were experimentally in the range of 109.51–139.55 ppm, as they theoretically were in the range of 127.33–148.39 ppm. Experimentally, the pyrimidine ring carbonyl carbon C8 was at 153.41 ppm, and the aliphatic carbonyl carbon C11 was at 155.22 ppm. Meanwhile, their theoretical corresponding values of C8 and C11 were at 159.73 and 160.06 ppm, respectively. The agreement between the experimental and theoretical NMR results points out that the DHFP was synthesized successfully while theoretical calculations confirm the molecular structure of the DHFP.

3.4. Experimental and theoretical vibration frequencies

The experimental vibration values were obtained by Perkin Elmer FTIR/FIR Spectrophotometer Frontier, while theoretical vibrations were calculated using DFT/B3LYP method and the 6-311++G (2d, p) basis set. The structure of DHFP contains 33 atoms which theoretically gave 93 normal vibrational modes. The experimental and theoretical FTIR spectra of DHFP, shown in Fig. 3, were analyzed based on characteristic peaks such as amine, aromatic, carbonyl, and CH2 vibrations. In addition, the experimental FTIR frequencies are listed in Table 4 together with their corresponding calculated values. The theoretical data in the table also reflects the details of the percentage potential energy distribution (PED) and vibrational mode assignments. The experimental and theoretical vibrational spectra are found to be compatible.

Fig. 3.

Fig. 3

Experimental and theoretical FTIR spectrum of DHFP.

Table 4.

Experimental and theoretical FTIR values of DHFP (cm−1) (selected). The atom labels can be followed from Fig. 2.

Exp. Theo.
Vibration assignment (PED)
Unscaled Scaled
3694 3623 3483 νN9H25 (100)
3652 3486 3351 νN3H26 (99)
3226 3286 3159 νC4H22 (95)
3158 3271 3144 νC1H21 (95)
3061 3186 3063 νC16H29, νC17H30, νC18H31, νC19H32 (93)
3178 3055 νC16H29, νC17H30, νC18H31, νC19H32 (96)
3170 3047 νC16H29, νC17H30, νC18H31, νC19H32 (87)
3042 3160 3038 δC16C17C18 (87)
3023 3151 3029 νC20H33 (77)
3140 3018 νC6H24 (98)
2965 3109 2989 νC14H27 (80),
νC14H28 (20)
2926 3054 2936 νC14H27 (20),
νC14H28 (80)
2888 3010 2894 νC6H23 (98)
1723 1747 1679 νC8O10, νC11O12 (63),
νN3C11 (11)
1654 1701 1635 νC8O10, νC11O12 (66)
1622 1572 1511 νN13C11 (18),
δH26N13C14 (58)
1522 1516 1457 δH24C6H23 (72)
1465 1490 1432 δH31C18C19, δH27C14C15, δH30C17C18, δH32C19C20 (55)
1480 1423 δH28C14H27 (91)
1402 1472 1415 δH25N9C3 (31)
1383 1431 1376 νC1C2, νC2C6, νN7C8 (34),
δH24C6H23 (15)
1358 1402 1348 νC3C4 (15),
δH25N9C3 (26)
1308 1388 1334 τH27C14C15C16, τH28C14C15C16 (80)
1264 1328 1277 νN9C8 (13),
δH21C1O5, δH22C4O5 (35)
1239 1299 1249 δH23C6C2 (40)
1214 1280 1230 νC15C20, νC16C17, νC17C18 (12),
δH27C14C15, δH29C16C17, δH33C20C19 (13) τH28C14C15C16 (26),
1195 1236 1188 νC3C4 (13)
1151 1225 1178 νC14C15 (18),
νN13C11 (10)
1132 1220 1173 νC14C15 (20),
δH29C16C17, δH30C17C18, δH32C19C20, δH33C20C19 (10)
1101 1171 1126 νO5C1, νO5C4 (14),
δC6C2C1 (13),
δC3C4O5, δC1O5C4 (12)
1082 1114 1071 νC15C20, νC17C18 (11),
δH27C14C15, δH29C16C17, δH33C20C19 (21)
1025 1102 1059 νN13C14 (10)
1050 1009 νO5C1, νO5C4 (58),
δH21C1O5 δH22C4O5 (14)
968 1041 1001 νN13C14 (23),
886 918 882 δC3C4O5 (12),
δC1O5C4 (52)
848 863 830 δC1O5C4 (18),
δN7C11N13, δN9C8O10 (10)
746 790 759 τC2C1O5C4, τC1O5C4C3 (15),
τH21C1O5C4 (63)
741 769 739 δC16C17C18, δC18C19C20, δC17C18C19 (10) τH31C18C19C20, τH32C19C20C15, τH33C20C19C18 (20), γO12N13N7C11 (41)
759 730 γO10N9N7C8 (82)
699 714 686 τH31C18C19C20, τH32C19C20C15, τH33C20C19C18 (45)
667 713 685 τH22C4O5C1 (40)
642 676 650 δC6C2C1 (17),
δN7C11N13, δN9C8O10 (13)
611 660 634 τH26N13C11N7 (76)
579 608 585 δO12C11N13 (14),
τC2C1O5C4, τC1O5C4C3 (58)
523 532 511 τH25N9C3C2 (40)
479 515 495 τH25N9C3C2 (28)

Experimental: exp., theoretical: theo., PED: potential energy distribution, ν: stretching, δ: in-plane bending, γ: out-of-plane bending, τ: torsion.

3.4.1. NH vibrations

The stretching vibrations of the amide NH bond observe around 3300-3600 cm−1 [5355]. In the DHFP, N9H25 and N13H26 stretching vibrations were theoretically observed at 3483 and 3351 cm−1, as seen experimentally at 3623 and 3486 cm−1. Furthermore, H25N9C3 and H26N13C14 in-plane bending vibrations were observed theoretically at 1511 and 1415 cm−1 and experimentally at 1622 and 1402 cm−1. The H25N9C3C2 torsional vibration was observed theoretically at 511 cm−1 and experimentally at 523 cm−1.

3.4.2. Aromatic CH vibrations

Aromatic CH bond stretching vibrations are usually just over 3000 cm−1 [54,56]. There are seven aromatic CH on the DHFP structure, and their vibrational values were very close to each other. These CH stretching vibrations were theoretically observed in the range of 3029-3159 cm−1, and experimentally in the range of 3023-3226 cm−1, respectively. These atoms in-plane bending vibrations of these atoms theoretically observed in the range of 1432-1537 cm−1 while they were experimentally in the range of 1465-1622 cm−1.

3.4.3. Carbonyl vibrations

Depending on the electronegative atoms attached to the carbonyl group, the carbonyl group gives a stretching vibration in the range of 1650-1800 cm−1 [53,54,57]. There are two different carbonyl groups in the DHFP structure, but since both are located between N–N they gave the same experimental and theoretical vibrations value. While C8O10 and C11O12 stretching frequencies were theoretically at 1679 cm −1, experimentally at 1723 cm−1. In addition, N9C8O10 and O12C11N13 in-plane bending vibrations were theoretically observed at 650 and 585 cm−1, and experimentally at 642 and 579 cm−1.

3.4.4. CH2 vibrations

The characteristic vibration of the CH2 is the stretching vibration in the range of 2900-3000 cm−1 and the in-plane bending vibration around 1450 cm−1 [58]. The C6H23, C6H24, C14H27 and C14H28 stretching vibrations were observed theoretically in the range of 2894-3018 cm−1, and experimentally in the range of 2888-2965 cm−1. In-plane bending vibration of these atoms was observed theoretically at 1376, 1423 and 1432 cm−1 and experimentally at 1383 and 1465 cm−1.

3.5. HOMO-LUMO analysis and electronic properties

Frontier Molecular Orbital (FMO) deals with the calculation of the highest occupied molecular orbital (HOMO) and the lowest unoccupied molecular orbital (LUMO) energy levels. Thus, information about the reactivity and physical properties of the molecule is obtained. HOMO indicates the electron-donating ability and is used to calculate the Ionization Potential (IP), while LUMO refers to the electron-accepting ability and is used for the calculation of Electron Affinity (EA). The energy difference between HOMO and LUMO tells us a lot about molecules. If the energy difference between two orbitals is less, the molecule is more polarized, with high softness, low hardness, and high chemical reactivity [52,[59], [60], [61]]. If the energy difference between two orbitals is large, they are vice versa.

The HOMO and LUMO energies of the DHFP were calculated using the B3LYP theory and the 6-311++G (2d, p) base set. The molecular orbitals for the calculated HOMO and LUMO energies are shown in Fig. 4. Here Gaussian output values in the atomic unit (a.u.), were converted to electrostatic units (1 a.u. = 27.2116 eV) [62,63].

Fig. 4.

Fig. 4

HOMO and LUMO energy levels for DHFP.

The Ionization Potential (IP), Electron Affinity (EA), Electronegativity (χ), Chemical Potential (μ), Chemical Hardness (η), and Chemical Softness (s) for DHFP were calculated using HOMO and LUMO values. Molecular electrical properties were obtained by using HOMO and LUMO energies and the results were given in Table 5. In summary, the low value of ΔE, calculated as 5.8182 eV, proves the high chemical reactivity of the DHFP molecular structure.

Table 5.

Electronic structure values of DHFP.

EHOMO(eV) ELUMO(eV) ΔE (eV) IP(eV) EA (eV) χ (eV) φ (eV) η (eV) σ (eV−1)
−6.4320 −0.6138 5.8182 6.4320 0.6138 3.5229 −3.5229 2.9091 0.3437

IP= Ionization Potential = -HOMO, EA = Electron Affinity = -LUMO.

χ = Electronegativity = (IP + EA)/2, φ = Chemical potential = - χ,

η = Chemical hardness = (IP-EA)/2, σ = Chemical softness = 1/η.

3.6. Molecular electrostatic potential surface

The molecular electrostatic potential (MEP) map, if calculated, shows the positive and negative regions of the molecule and allows us to gain insight into the chemical reactivity of the molecule. The MEP of DHFP calculated is shown in Fig. 5. It shows the positive parts of the molecule in blue, the negative parts in red, and the neutral parts in green [53,[64], [65], [66]].

Fig. 5.

Fig. 5

Molecular electrostatic potential map for DHFP.

When the MEP of the DHFP was examined in Fig. 5, the negative regions (red region) were found localized on the oxygen atoms as the positive regions (blue region) localized on the hydrogen atoms. This indicates possible sites for nucleophilic attack.

3.7. Anticancer activity

The cytotoxicity of the DHFP has been examined by MTT assay towards human colon cancer HT29 and prostate cancer DU145 cell lines. The dose application times were 24 h and 48 h. The cell viability percentages of HT29 and DU145 are shown depending on doses in Fig. 6A and B, respectively. In 24-h dose application on HT29 cells, the growth of cell lines remained above 50 percent on average in the x - y dose range. In the 48-h test on the same cells, there was no significant change in cell viability compared to the 24 h test. The inhibitory effects of DHFP on DU145 cells for 24 h dose application exhibited over 70% viability even for the highest dose (300 ppm). However, DHFP was effective on DU145 in 48 h application as 59.13% death was observed for 300 ppm dose. The IC50 value is found to be 17.4 ppm. This sharp difference between 24 h and 48 h dose application may be due to the aggressive properties of prostate cancer cells. The MTT studies have determined that DHFP showed a higher inhibition on DU145 compared to the HT29 cell line. According to these results, DHFP exhibited reasonable anticancer activity against HT29 while it showed a potent activity on DU145 cells.

Fig. 6.

Fig. 6

A: The cytotoxic effect of DHFP on HT29 cell line, B: The cytotoxic effect of DHFP on DU145 cell line.

To the best of our knowledge, there is no study that evaluates the anticancer effect of furo- [3,4-d] pyrimidine compounds. The closest examples are given by the two investigation of the anticancer effects of pyrimidine-based compounds on HT29 and DU145 cells [67,68]. It was seen that DHFP was effective at higher doses in comparison with the doses applied in these latter studies.

3.8. Molecular docking analysis

The epidermal growth factor receptor (EGFR) has an important role in cell growth and division. The amount of EGFR protein is above normal in some types of cancer cells such as colorectal cancer, head and neck cancer, lung cancer, and breast cancer. It causes cancer cells to divide faster and grow faster. Thus, EGFR tyrosine kinase inhibitors are used as a drug in cancer treatment [69,70].

In this context, molecular docking studies become crucial as they provide an opportunity to gain information about ligand-receptor interaction before any experimental drug test. It can be found out which region of the protein the ligand binds to, what kind of interactions it makes, and their binding energies in these docking calculations [71,72]. The molecular docking calculations of various furopyrimidine compounds have shown that they behave as an inhibitor of EGFR tyrosine kinase [[17], [18], [19],73,74]. To have an idea about if the compound DHFP can carry the potential of being an inhibitor as a molecule containing furopyrimidine ring, we carried out docking calculations on its effect on EGFR tyrosine kinase (PDB ID:1M17). Amongst the calculated docking positions, the lowest energy protein-ligand binding was selected. The selected docking pose demonstrated that the binding energy of DHFP and EGFR tyrosine kinase was found to be −7.4 kcal/mol. Although this binding energy value is higher than that of the standard drug erlotinib which has been given as −10.6 kcal/mol [67], the DHFP does hydrogen bonds and hydrophobic interactions, as expected from an anticancer agent. The binding sites of DHFP to EGFR tyrosine kinase are shown in Fig. 7A from which DHFP interacts close to the binding site of erlotinib in the EGFR tyrosine kinase structure. These interactions are hydrophobic with PHE699, VAL702, and ASP831 and hydrogen bonds with ASP813 and ARG817 amino acids in EGFR tyrosine kinase, as all interactions are shown in Fig. 7B. Moreover, it is seen in Fig. 7C that N9 in the DHFP structure is both a hydrogen bond acceptor and donor in the two different interactions.

Fig. 7.

Fig. 7

A: The binding site of DHFP and erlotinib on EGFR tyrosine kinase structure, B: detailed illustration of interactions between DHFP and EGFR tyrosine kinase and C: detailed illustration of H bonds between DHFP and EGFR tyrosine kinase.

3.9. Evaluation of pharmacokinetics and drug-likeness properties of DHFP

By evaluating the pharmacokinetic, toxicity, and bioavailability properties of the compounds, their use or development as drugs can be achieved [6870]. As shown in Table 6, DHFP follows the Lipinski rule (molecular weight ≤500, number of H bond acceptor ≤5, number of H bond donor ≤5, TPSA/A2≤140, log P ≤ 5) as a drug candidate. According to the ADME result, DHFP has a high GI (gastrointestinal) absorption value means that the drug is rapidly absorbed.

Table 6.

Data of Lipinski rule, Pharmacokinetics, and Drug likeness.

Mw NBR HBA HBD TPSA/A2 (≤140) Consensus
Log Po/w
Lipinski Rule
Bioavailability
Score
GI abs.
result violation
271.27 4 3 2 74.58 1.47 yes 0 0.55 High

Mw: Molecular weight, NBR: Number of rotatable bonds, HBA: Number of Hydrogen bond acceptors, HBD: Number of Hydrogen bond donors, TPSA: Topological polar surface area, Consensus Log Po/w: Log Poctane/water, GI: Gastrointestinal.

The ADMET data of the DHFP which is computationally forecasted from its given molecular structure are shown in Table 7. It is exhibited that the DHFP has oral bioavailability, is rapidly absorbed in the human intestine, and can cross the blood-brain barrier. In addition, mitochondria provide the subcellular localization of DHFP. DHFP is not a P-glycoprotein inhibitor or substrate. Since, P-glycoprotein pumps drugs back into the lumen, reducing the drug absorption, it can be said that the bioavailability and bioactivity of the DHFP is high.

Table 7.

Pharmacokinetics and ADMET data.

Human Intestinal Absorption (<0.25 poor,
>0.80 high)
Human oral bioavailability Caco-2 (<0.25 poor,
>50 great
Blood Brain Barrier Subcellular localization P-glycoprotein inhibitor P- glycoprotein substrate
0.9640 yes 0.7279 yes mitochondria No no

4. Conclusions

Novel N-benzyl-2-oxo-1,2-dihydrofuro [3,4-d]pyrimidine-3(4H)-carboxamide was synthesized with a very good yield in the present study. NMR and FTIR spectra confirm the expected structure of DHFP, while the mass spectrum is 100% compatible with the calculated mass of the compound, indicating high purity. Its molecular configuration was determined theoretically by DFT calculations. DHFP bounds to EGFR tyrosine kinase near Erlotinib. Therefore, we thought that it could be a potential anticancer agent and determined effective anticancer activity in colon and prostate cancer cells. The biological properties of DHFP can be further investigated, as ADME and ADMET calculations reveal its high bioavailability. For future studies, it would be desirable to synthesize different derivatives of 1,2-dihydrofuro [3,4-d]pyrimidine and additional studies are required to determine their mechanism as a potential anticancer agent.

Author contribution statement

Ayşen Şuekinci Yılmaz: Conceived and designed the experiments; Performed the experiments; Analyzed and interpreted the data; Contributed reagents, materials, analysis tools or data; Wrote the paper.

Gühergül Uluçam: Conceived and designed the experiments; Analyzed and interpreted the data; Wrote the paper.

Funding statement

Dr. Ayşen Şuekinci Yılmaz was supported by Trakya Üniversitesi (TUBAP:2018/199).

Data availability statement

No data was used for the research described in the article.

Declaration of interest’s statement

The authors declare no conflict of interest.

Acknowledgements

The authors are indebted to Trakya University Scientific Research Projects Coordination Unit (TUBAP 2018/199) for financial support for this work. We thank the Trakya University Technology Research Development Application and Research Center (TUTAGEM) for the Q-TOF, FTIR, and cytotoxicity analyses.

Footnotes

Appendix A

Supplementary data related to this article can be found at https://doi.org/10.1016/j.heliyon.2023.e12948.

Appendix A. Supplementary data

The following is the supplementary data related to this article:

Multimedia component 1
mmc1.docx (405.3KB, docx)

References

  • 1.Lamie P.F., Philoppes J.N. Design, synthesis, stereochemical determination, molecular docking study, in silico pre-ADMET prediction and anti-proliferative activities of indole-pyrimidine derivatives as Mcl-1 inhibitors. Bioorg. Chem. 2021;116 doi: 10.1016/j.bioorg.2021.105335. [DOI] [PubMed] [Google Scholar]
  • 2.Basyouni W.M., Abbas S.Y., El-Bayouki K.A., Dawood R.M., El Awady M.K., Abdelhafez T.H. Synthesis and antiviral screening of 2‐(propylthio)‐7‐substituted‐thiazolo [5, 4‐d] pyrimidines as anti‐bovine viral diarrhea virus agents. J. Heterocycl. Chem. 2021;58(9):1766–1774. doi: 10.1002/jhet.4307. [DOI] [Google Scholar]
  • 3.Ballesteros-Casallas A., Paulino M., Vidossich P., Melo C., Jiménez E., Castillo J.-C., Portilla J., Miscione G.P. Synthesis of 2, 7-diarylpyrazolo [1, 5-a] pyrimidine derivatives with antitumor activity. Theoretical identification of targets. Eur. J. Med. Chem. Rep. 2022;4 doi: 10.1016/j.ejmcr.2021.100028. [DOI] [Google Scholar]
  • 4.Abdel-Aziz S.A., Taher E.S., Lan P., Asaad G.F., Gomaa H.A., El-Koussi N.A., Youssif B.G. Design, synthesis, and biological evaluation of new pyrimidine-5-carbonitrile derivatives bearing 1, 3-thiazole moiety as novel anti-inflammatory EGFR inhibitors with cardiac safety profile. Bioorg. Chem. 2021;111 doi: 10.1016/j.bioorg.2021.104890. [DOI] [PubMed] [Google Scholar]
  • 5.Katariya K.D., Reddy D.V. Oxazolyl-pyrimidines as antibacterial and antitubercular agents: synthesis, biological evaluation, in-silico ADMET and molecular docking study. J. Mol. Struct. 2022;1253 doi: 10.1016/j.molstruc.2021.132240. [DOI] [Google Scholar]
  • 6.Aksinenko A.Y., Goreva T.V., Epishina T.A., Trepalin S.V., Sokolov V.B. Synthesis of bis (trifluoromethyl) pyrimido [4, 5-d] pyrimidine-2, 4-diones and evaluation of their antibacterial and antifungal activities. J. Fluor. Chem. 2016;188:191–195. doi: 10.1016/j.jfluchem.2016.06.019. [DOI] [Google Scholar]
  • 7.Ali F., Khan K.M., Salar U., Iqbal S., Taha M., Ismail N.H., Perveen S., Wadood A., Ghufran M., Ali B. Dihydropyrimidones: as novel class of β-glucuronidase inhibitors. Bioorg. Med. Chem. 2016;24(16):3624–3635. doi: 10.1016/j.bmc.2016.06.002. [DOI] [PubMed] [Google Scholar]
  • 8.Manzoor S., Prajapati S.K., Majumdar S., Raza M.K., Gabr M.T., Kumar S., Pal K., Rashid H., Kumar S., Krishnamurthy S. Discovery of new phenyl sulfonyl-pyrimidine carboxylate derivatives as the potential multi-target drugs with effective anti-Alzheimer’s action: design, synthesis, crystal structure and in-vitro biological evaluation. Eur. J. Med. Chem. 2021;215 doi: 10.1016/j.ejmech.2021.113224. [DOI] [PubMed] [Google Scholar]
  • 9.Raju K.S., AnkiReddy S., Sabitha G., Krishna V.S., Sriram D., Reddy K.B., Sagurthi S.R. Synthesis and biological evaluation of 1H-pyrrolo [2, 3-d] pyrimidine-1, 2, 3-triazole derivatives as novel anti-tubercular agents. Bioorg. Med. Chem. Lett. 2019;29(2):284–290. doi: 10.1016/j.bmcl.2018.11.036. [DOI] [PubMed] [Google Scholar]
  • 10.Scappini B., Gianfaldoni G., Caracciolo F., Mannelli F., Biagiotti C., Romani C., Pogliani E.M., Simonetti F., Borin L., Fanci R. Cytarabine and clofarabine after high‐dose cytarabine in relapsed or refractory AML patients. Am. J. Hematol. 2012;87(12):1047–1051. doi: 10.1002/ajh.23308. [DOI] [PubMed] [Google Scholar]
  • 11.Halbrook C.J., Pontious C., Kovalenko I., Lapienyte L., Dreyer S., Lee H.-J., Thurston G., Zhang Y., Lazarus J., Sajjakulnukit P. Macrophage-released pyrimidines inhibit gemcitabine therapy in pancreatic cancer. Cell Metabol. 2019;29(6):1390–1399. doi: 10.1016/j.cmet.2019.02.001. e6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Fei X., Wang J.-Q., Miller K.D., Sledge G.W., Hutchins G.D., Zheng Q.-H. Synthesis of [18F] Xeloda as a novel potential PET radiotracer for imaging enzymes in cancers. Nucl. Med. Biol. 2004;31(8):1033–1041. doi: 10.1016/j.nucmedbio.2004.02.006. [DOI] [PubMed] [Google Scholar]
  • 13.Verissimo L.M., Cabral I., Cabral A.M., Utzeri G., Veiga F.J., Valente A.J., Ribeiro A.C. Transport properties of aqueous solutions of the oncologic drug 5-fluorouracil: a fundamental complement to therapeutics. J. Chem. Therm. 2021;161 doi: 10.1016/j.jct.2021.106533. [DOI] [Google Scholar]
  • 14.Abd El-Mageed M.M., Eissa A.A., Farag A.E.-S., Osman E.E.A. Design and synthesis of novel furan, furo [2, 3-d] pyrimidine and furo [3, 2-e][1, 2, 4] triazolo [1, 5-c] pyrimidine derivatives as potential VEGFR-2 inhibitors. Bioorg. Chem. 2021;116 doi: 10.1016/j.bioorg.2021.105336. [DOI] [PubMed] [Google Scholar]
  • 15.Gregorić T., Sedić M., Grbčić P., Paravić A.T., Pavelić S.K., Cetina M., Vianello R., Raić-Malić S. Novel pyrimidine-2, 4-dione–1, 2, 3-triazole and furo [2, 3-d] pyrimidine-2-one–1, 2, 3-triazole hybrids as potential anti-cancer agents: synthesis, computational and X-ray analysis and biological evaluation. Eur. J. Med. Chem. 2017;125:1247–1267. doi: 10.1016/j.ejmech.2016.11.028. [DOI] [PubMed] [Google Scholar]
  • 16.Ahmed E.Y., Latif N.A.A., El-Mansy M.F., Elserwy W.S., Abdelhafez O.M. VEGFR-2 inhibiting effect and molecular modeling of newly synthesized coumarin derivatives as anti-breast cancer agents. Bioorg. Med. Chem. 2020;28(5) doi: 10.1016/j.bmc.2020.115328. [DOI] [PubMed] [Google Scholar]
  • 17.Hossam M., Lasheen D.S., Ismail N.S., Esmat A., Mansour A.M., Singab A.N.B., Abouzid K.A. Discovery of anilino-furo [2, 3-d] pyrimidine derivatives as dual inhibitors of EGFR/HER2 tyrosine kinase and their anticancer activity. Eur. J. Med. Chem. 2018;144:330–348. doi: 10.1016/j.ejmech.2017.12.022. [DOI] [PubMed] [Google Scholar]
  • 18.Han J., Kaspersen S.J., Nervik S., Nørsett K.G., Sundby E., Hoff B.H. Chiral 6-aryl-furo [2, 3-d] pyrimidin-4-amines as EGFR inhibitors. Eur. J. Med. Chem. 2016;119:278–299. doi: 10.1016/j.ejmech.2016.04.054. [DOI] [PubMed] [Google Scholar]
  • 19.Wang T., Wu F., Luo L., Zhang Y., Ma J., Hu Y. Efficient synthesis and cytotoxic activity of polysubstituted thieno [2, 3-d] pyrimidine derivatives. J. Mol. Struct. 2022;1256 doi: 10.1016/j.molstruc.2022.132497. [DOI] [Google Scholar]
  • 20.Gaussian09 R.A., frisch mj, trucks gw, schlegel hb, scuseria ge, robb ma, cheeseman jr, Scalmani g., Barone v., Mennucci b., petersson ga, et al. Vol. 121. 2009. Gaussian, Inc., Wallingford CT; pp. 150–166. 1. [Google Scholar]
  • 21.Daina A., Michielin O., Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017;7(1):1–13. doi: 10.1038/srep42717. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Yang H., Lou C., Sun L., Li J., Cai Y., Wang Z., Li W., Liu G., Tang Y. admetSAR 2.0: web-service for prediction and optimization of chemical ADMET properties. Bioinformatics. 2019;35(6):1067–1069. doi: 10.1093/bioinformatics/bty707. [DOI] [PubMed] [Google Scholar]
  • 23.Yılmaz A.Ş., Kaçan M. New synthesis of novel 1, 2-dihydrofuro [3, 4-d] pyrimidines. Tetrahedron. 2017;73(31):4509–4512. doi: 10.1016/j.tet.2017.05.072. [DOI] [Google Scholar]
  • 24.Qu R., Zhang X., Zhang Q., Yang X., Wang Z., Wang L. Experimental and theoretical study on IR and NMR spectra of several tetrachlorinated diphenyl sulfides. Spectrochim. Acta Mol. Biomol. Spectrosc. 2011;81(1):261–269. doi: 10.1016/j.saa.2011.06.008. [DOI] [PubMed] [Google Scholar]
  • 25.Uluçam G., Okan S.E., Aktaş Ş., Öğretmen G.P. Characterization of dinaphthosulfoxide molecule. J. Mol. Struct. 2015;1102:146–152. doi: 10.1016/j.molstruc.2015.08.051. [DOI] [Google Scholar]
  • 26.Manikandan D., Swaminathan J., Tagore S.S., Gomathi S., Sabarinathan N., Ramalingam M., Balasubramani K., Sethuraman V. Crystallographic, spectral and computational studies on (S)-4-(4-aminobenzyl) oxazolidin-2-one. Spectrochim. Acta Mol. Biomol. Spectrosc. 2020;239 doi: 10.1016/j.saa.2020.118484. [DOI] [PubMed] [Google Scholar]
  • 27.Foresman J., Frish E. Gaussian Inc.; Pittsburg, USA: 1996. Exploring Chemistry. [Google Scholar]
  • 28.Arslan N.B., Özdemir N., Dayan O., Dege N., Koparır M., Koparır P., Muğlu H. Direct and solvent-assisted thione–thiol tautomerism in 5-(thiophen-2-yl)-1, 3, 4-oxadiazole-2 (3H)-thione: experimental and molecular modeling study. Chem. Phys. 2014;439:1–11. doi: 10.1016/j.chemphys.2014.05.006. [DOI] [Google Scholar]
  • 29.Zare Fekri L., Nikpassand M., Goldoost M. Synthesis, experimental and DFT studies on crystal structure, FT-IR, 1H, and 13C NMR spectra, and evaluation of aromaticity of three derivatives of xanthens. Russ. J. Gen. Chem. 2013;83(12):2352–2360. doi: 10.1134/S107036321312027X. [DOI] [Google Scholar]
  • 30.Turkyilmaz M., Uluçam G., Aktaş Ş., Okan S.E. Synthesis and characterization of new N-heterocyclic carbene ligands: 1, 3-Bis (acetamide) imidazole-3-ium bromide and 3-(acetamide)-1-(3-aminopropyl)-1H-imidazole-3-ium bromide. J. Mol. Struct. 2017;1136:263–270. doi: 10.1016/j.molstruc.2017.02.022. [DOI] [Google Scholar]
  • 31.Sayin K., Karakaş D. Structural, spectral, NLO and MEP analysis of the [MgO2Ti2 (OPri) 6],[MgO2Ti2 (OPri) 2 (acac) 4] and [MgO2Ti2 (OPri) 2 (bzac) 4] by DFT method. Spectrochim. Acta Mol. Biomol. Spectrosc. 2015;144:176–182. doi: 10.1016/j.saa.2015.02.086. [DOI] [PubMed] [Google Scholar]
  • 32.Uluçam G., Okan Ş.E., Aktaş Ş., Yentürk B. New Schiff-base ligands containing thiophene terminals: synthesis, characterization and biological activities. J. Mol. Struct. 2021;1230 doi: 10.1016/j.molstruc.2021.129941. [DOI] [PubMed] [Google Scholar]
  • 33.Devi K.S., Subramani P., Parthiban S., Sundaraganesan N. One-pot synthesis, spectroscopic characterizations, quantum chemical calculations, docking and cytotoxicity of 1-((dibenzylamino) methyl) pyrrolidine-2, 5-dione. J. Mol. Struct. 2020;1203 doi: 10.1016/j.molstruc.2019.127403. [DOI] [Google Scholar]
  • 34.Uluçam G., Bagcı U., Yılmaz A.Ş., Yentürk B. Schiff-base ligands containing phenanthroline terminals: synthesis, characterization, biological activities and molecular docking study. Spectrochim. Acta Mol. Biomol. Spectrosc. 2022;279 doi: 10.1016/j.saa.2022.121429. [DOI] [PubMed] [Google Scholar]
  • 35.Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods. 1983;65(1–2):55–63. doi: 10.1016/0022-1759(83)90303-4. [DOI] [PubMed] [Google Scholar]
  • 36.Boy S., Aras A., Türkan F., Akyıldırım O., Beytur M., Sedef Karaman H., Manap S., Yüksek H. Synthesis, spectroscopic analysis, and in vitro/in silico biological studies of novel piperidine derivatives heterocyclic schiff‐mannich base compounds. Chem. Biodivers. 2021;18(12) doi: 10.1002/cbdv.202100433. [DOI] [PubMed] [Google Scholar]
  • 37.Zhen Y., Shan X., Li Y., Lin Z., Zhang L., Lai C., Qin F. Phytomedicine Plus; 2022. Exploring the Potential Mechanism of Radix Astragali against Ischemic Stroke Based on Network Pharmacology and Molecular Docking. [DOI] [Google Scholar]
  • 38.Yadav V., Krishnan A., Baig M.S., Majeed M., Nayak M., Vohora D. Decrypting the interaction pattern of Piperlongumine with calf thymus DNA and dodecamer d (CGCGAATTCGCG) 2 B-DNA: biophysical and molecular docking analysis. Biophys. Chem. 2022;285 doi: 10.1016/j.bpc.2022.106808. [DOI] [PubMed] [Google Scholar]
  • 39.Anju K., Shoba G., Sumita A., Balakumaran M.D., Vasanthi R., Kumaran R. Interaction of acridinedione dye with a globular protein in the presence of site selective and site specific binding drugs: photophysical techniques assisted by molecular docking methods. Spectrochim. Acta Mol. Biomol. Spectrosc. 2021;258 doi: 10.1016/j.saa.2021.119814. [DOI] [PubMed] [Google Scholar]
  • 40.Crampon K., Giorkallos A., Deldossi M., Baud S., Steffenel L.A. Machine-learning methods for ligand–protein molecular docking. Drug Discov. Today. 2021 doi: 10.1016/j.drudis.2021.09.007. [DOI] [PubMed] [Google Scholar]
  • 41.Trott O., Olson A.J., Vina AutoDock. Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J. Comput. Chem. 2010;31(2):455–461. doi: 10.1002/jcc.21334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42.Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock 4 and AutoDockTools 4: automated docking with selective receptor flexibility. J. Comput. Chem. 2009;30(16):2785–2791. doi: 10.1002/jcc.21256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Stamos J., Sliwkowski M.X., Eigenbrot C. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 2002;277(48):46265–46272. doi: 10.1074/jbc.M207135200. [DOI] [PubMed] [Google Scholar]
  • 44.Chalkha M., el Hassani A.A., Nakkabi A., Tüzün B., Bakhouch M., Benjelloun A.T., Sfaira M., Saadi M., El Ammari L., El Yazidi M. Crystal structure, Hirshfeld surface and DFT computations, along with molecular docking investigations of a new pyrazole as a tyrosine kinase inhibitor. J. Mol. Struct. 2023;1273 doi: 10.1016/j.molstruc.2022.134255. [DOI] [Google Scholar]
  • 45.Masand V.H., Rastija V. PyDescriptor: a new PyMOL plugin for calculating thousands of easily understandable molecular descriptors. Chemometr. Intell. Lab. Syst. 2017;169:12–18. doi: 10.1016/j.chemolab.2017.08.003. [DOI] [Google Scholar]
  • 46.DeLano W.L. 2002. The PyMOL Molecular Graphics System. [Google Scholar]
  • 47.Pettersen E.F., Goddard T.D., Huang C.C., Couch G.S., Greenblatt D.M., Meng E.C., Ferrin T.E. UCSF Chimera—a visualization system for exploratory research and analysis. J. Comput. Chem. 2004;25(13):1605–1612. doi: 10.1002/jcc.20084. [DOI] [PubMed] [Google Scholar]
  • 48.Adasme M.F., Linnemann K.L., Bolz S.N., Kaiser F., Salentin S., Haupt V.J., Schroeder M. PLIP 2021: expanding the scope of the protein–ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 2021;49(W1):W530–W534. doi: 10.1093/nar/gkab294. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Lipinski C.A. Lead-and drug-like compounds: the rule-of-five revolution. Drug Discov. Today Technol. 2004;1(4):337–341. doi: 10.1016/j.ddtec.2004.11.007. [DOI] [PubMed] [Google Scholar]
  • 50.Cheng F., Li W., Zhou Y., Shen J., Wu Z., Liu G., Lee P.W., Tang Y. ACS Publications; 2012. admetSAR: a Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties. [DOI] [PubMed] [Google Scholar]
  • 51.Demircioğlu Z., Kaştaş Ç.A., Büyükgüngör O. Theoretical analysis (NBO, NPA, Mulliken Population Method) and molecular orbital studies (hardness, chemical potential, electrophilicity and Fukui function analysis) of (E)-2-((4-hydroxy-2-methylphenylimino) methyl)-3-methoxyphenol. J. Mol. Struct. 2015;1091:183–195. doi: 10.1016/j.molstruc.2015.02.076. [DOI] [Google Scholar]
  • 52.Obu Q.S., Louis H., Odey J.O., Eko I.J., Abdullahi S., Ntui T.N., Offiong O.E. Synthesis, spectra (FT-IR, NMR) investigations, DFT study, in silico ADMET and Molecular docking analysis of 2-amino-4-(4-aminophenyl) thiophene-3-carbonitrile as a potential anti-tubercular agent. J. Mol. Struct. 2021;1244 doi: 10.1016/j.molstruc.2021.130880. [DOI] [Google Scholar]
  • 53.Anwer K.E., Sayed G.H., Ramadan R.M. Synthesis, spectroscopic, DFT calculations, biological activities and molecular docking studies of new isoxazolone, pyrazolone, triazine, triazole and amide derivatives. J. Mol. Struct. 2022;1256 doi: 10.1016/j.molstruc.2022.132513. [DOI] [Google Scholar]
  • 54.Śmiszek-Lindert W.E., Chełmecka E., Lindert O., Dudzińska A., Kaczmarczyk-Sedlak I. Towards a better comprehension of interactions in the crystalline N-acetylbenzylamine and its sulphur analogue N-benzyl-ethanethioamide. IR, Raman, DFT studies and Hirshfeld surfaces analysis. Spectrochim. Acta Mol. Biomol. Spectrosc. 2018;201:328–338. doi: 10.1016/j.saa.2018.05.021. [DOI] [PubMed] [Google Scholar]
  • 55.El Kalai F., Karrouchi K., Baydere C., Daoui S., Allali M., Dege N., Benchat N., Brandan S.A. Synthesis, crystal structure, spectroscopic studies, NBO, AIM and SQMFF calculations of new pyridazinone derivative. J. Mol. Struct. 2021;1223 doi: 10.1016/j.molstruc.2020.129213. [DOI] [Google Scholar]
  • 56.Umar Y. Experimental (FT-IR, FT-Raman, and NMR) and DFT studies of the structures and spectral properties of diphenylcarbazone and diphenylthiocarbazone. J. Mol. Struct. 2022;1264 doi: 10.1016/j.molstruc.2022.133230. [DOI] [Google Scholar]
  • 57.Sheena Mary Y., Shyma Mary Y., Serdaroglu G., Kaya S., Sarojini B., Umamahesvari H., Mohan B. Polycyclic Aromatic Compounds; 2021. Conformational Analysis, Spectroscopic Insights, Chemical Descriptors, ELF, LOL and Molecular Docking Studies of Potential Pyrimidine Derivative with Biological Activities; pp. 1–11. [DOI] [Google Scholar]
  • 58.Unsalan O., Szolnoki B., Toldy A., Marosi G. FT-IR spectral, DFT studies and detailed vibrational assignment on N, N′, N ″-tris (2-aminoethyl)-phosphoric acid triamide. Spectrochim. Acta Mol. Biomol. Spectrosc. 2012;98:110–115. doi: 10.1016/j.saa.2012.08.050. [DOI] [PubMed] [Google Scholar]
  • 59.Ouaket A., Chraka A., Raissouni I., El Amrani M.A., Berrada M., Knouzi N. Synthesis, spectroscopic (13C/1H-NMR, FT-IR) investigations, quantum chemical modelling (FMO, MEP, NBO analysis), and antioxidant activity of the bis-benzimidazole molecule. J. Mol. Struct. 2022;1259 doi: 10.1016/j.molstruc.2022.132729. [DOI] [Google Scholar]
  • 60.Abdou A., Omran O.A., Nafady A., Antipin I.S. Structural, spectroscopic, FMOs, and non-linear optical properties exploration of three thiacaix (4) arenes derivatives. Arab. J. Chem. 2022;15(3) doi: 10.1016/j.arabjc.2021.103656. [DOI] [Google Scholar]
  • 61.Ulucam G., Yenturk B., Okan S.E., Aktas S. Double vanadyl-carrying phenanthroline complexes: template synthesis and DFT study. Chem. Pap. 2020;74(6):1881–1889. doi: 10.1007/s11696-019-01037-9. [DOI] [Google Scholar]
  • 62.Vela A., Gazquez J.L. A relationship between the static dipole polarizability, the global softness, and the fukui function. J. Am. Chem. Soc. 1990;112(4):1490–1492. doi: 10.1021/ja00160a029. [DOI] [Google Scholar]
  • 63.Mary Y.S., Mary Y.S. DFT analysis and molecular docking studies of the cocrystals of sulfathiazole-theophylline and sulfathiazole-sulfanilamide. Polycycl. Aromat. Comp. 2022;42(6):3809–3820. doi: 10.1080/10406638.2021.1873809. [DOI] [Google Scholar]
  • 64.Boshaala A., Said M.A., Assirey E.A., Alborki Z.S., AlObaid A.A., Zarrouk A., Warad I. Crystal structure, MEP/DFT/XRD, thione⇔ thiol tautomerization, thermal, docking, and optical/TD-DFT studies of (E)-methyl 2-(1-phenylethylidene)-hydrazinecarbodithioate ligand. J. Mol. Struct. 2021;1238 doi: 10.1016/j.molstruc.2021.130461. [DOI] [Google Scholar]
  • 65.Kargar H., Fallah-Mehrjardi M., Behjatmanesh-Ardakani R., Munawar K.S., Ashfaq M., Tahir M.N. Diverse coordination of isoniazid hydrazone Schiff base ligand towards iron (III): synthesis, characterization, SC-XRD, HSA, QTAIM, MEP, NCI, NBO and DFT study. J. Mol. Struct. 2022;1250 doi: 10.1016/j.molstruc.2021.131691. [DOI] [Google Scholar]
  • 66.Demir S., Cakmak S., Dege N., Kutuk H., Odabasoglu M., Kepekci R.A. A novel 3-acetoxy-2-methyl-N-(4-methoxyphenyl) benzamide: molecular structural describe, antioxidant activity with use X-ray diffractions and DFT calculations. J. Mol. Struct. 2015;1100:582–591. doi: 10.1016/j.molstruc.2015.08.014. [DOI] [Google Scholar]
  • 67.Farag A.K., Ahn B.S., Yoo J.S., Karam R., Roh E.J. Design, synthesis, and biological evaluation of pseudo-bicyclic pyrimidine-based compounds as potential EGFR inhibitors. Bioorg. Chem. 2022 doi: 10.1016/j.bioorg.2022.105918. [DOI] [PubMed] [Google Scholar]
  • 68.Zarenezhad E., Farjam M., Iraji A. Synthesis and biological activity of pyrimidines-containing hybrids: focusing on pharmacological application. J. Mol. Struct. 2021;1230 doi: 10.1016/j.molstruc.2020.129833. [DOI] [Google Scholar]
  • 69.Woodburn J. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol. Therapeut. 1999;82(2–3):241–250. doi: 10.1016/S0163-7258(98)00045-X. [DOI] [PubMed] [Google Scholar]
  • 70.Traxler P., Furet P. Strategies toward the design of novel and selective protein tyrosine kinase inhibitors. Pharmacol. Therapeut. 1999;82(2–3):195–206. doi: 10.1016/S0163-7258(98)00044-8. [DOI] [PubMed] [Google Scholar]
  • 71.Medetalibeyoğlu H., Türkan F., Manap S., Bursal E., Beytur M., Aras A., Akyıldırım O., Kotan G., Gürsoy-Kol Ö., Yüksek H. Synthesis and acetylcholinesterase enzyme inhibitory effects of some novel 4, 5-Dihydro-1 H-1, 2, 4-triazol-5-one derivatives; an in vitro and in silico study. J. Biomol. Struct. Dyn. 2022:1–9. doi: 10.1080/07391102.2022.2066021. [DOI] [PubMed] [Google Scholar]
  • 72.Mary Y.S., Mary Y.S., Resmi K., Kumar V.S., Thomas R., Sureshkumar B. Detailed quantum mechanical, molecular docking, QSAR prediction, photovoltaic light harvesting efficiency analysis of benzil and its halogenated analogues. Heliyon. 2019;5(11) doi: 10.1016/j.heliyon.2019.e02825. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 73.Aliwaini S., Abu Thaher B., Al-Masri I., Shurrab N., El-Kurdi S., Schollmeyer D., Qeshta B., Ghunaim M., Csuk R., Laufer S. Design, synthesis and biological evaluation of novel pyrazolo [1, 2, 4] triazolopyrimidine derivatives as potential anticancer agents. Molecules. 2021;26(13):4065. doi: 10.3390/molecules26134065. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 74.Haddad Y., Remes M., Adam V., Heger Z. Toward structure-based drug design against the epidermal growth factor receptor (EGFR) Drug Discov. Today. 2021;26(2):289–295. doi: 10.1016/j.drudis.2020.10.007. [DOI] [PMC free article] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Multimedia component 1
mmc1.docx (405.3KB, docx)

Data Availability Statement

No data was used for the research described in the article.


Articles from Heliyon are provided here courtesy of Elsevier

RESOURCES